Formulation Development
BioAge Raises $90 Million to Treat Aging & Age-Related Diseases
BioAge Labs, Inc. recently announced it has raised $90 million in an oversubscribed Series C financing. The raise was co-led by Andreessen Horowitz and serial…
Excellence in Production: A Critical Contribution to the Pharmaceutical Industry
When it comes to the production of high-quality pharmaceuticals, excellence is the name of the game – in all production areas. It is the overarching goal of a well-defined course of action for….
WEBINAR ALERT! - Beyond Elemental Impurities: New Applications of ICP-MS
During this educational event, scientific experts will discuss several newer applications of ICP-MS in the pharmaceutical industry that capitalize on the technique’s versatility beyond the scope of elemental impurities.
Vectura Signs Development Agreement With Kinaset Therapeutics
Vectura Group plc recently announced it has signed a global outlicense and development agreement with Kinaset Therapeutics Inc. for the development and commercialization of….
Lonza Expands Development & Manufacturing Capabilities
Lonza recently announced a significant investment to expand its particle engineering and drug product capabilities to meet increased market demand at its Bend, OR, site…..
Kindeva & BOL Pharma Sign Agreement for Development of Inhaled Cannabinoid Products
Kindeva Drug Delivery and Breath of Life International recently signed an agreement to study the feasibility of multiple inhaled cannabinoid products…..
Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results
Galecto, Inc. recently announced the publication of a paper detailing full results from a Phase 2a study of GB0139 in Idiopathic Pulmonary Fibrosis (IPF) in…
Biogen & Sage Therapeutics Announce Global Development & Commercialization Collaboration
Biogen Inc. and Sage Therapeutics, Inc. recently announced they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for…
Samsung Biologics Breaks Ground on Super Plant, the World’s Largest & Most Innovative Bio-Manufacturing Facility
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea. Dubbed the "Super Plant,” the new, multi-story 238,000-square-meter construction will be the…
Baxter Biopharma Solutions Announces $50-Million Investment
Baxter International Inc. recently announced a $50-million expansion of its sterile fill/finish manufacturing facilities located in Bloomington, IN. These facilities are operated by Baxter’s BioPharma…
Gene Therapy Market to Surpass $6.21 Billion Globally, by 2027 at 13.4% CAGR
Allied Market Research published a report, titled Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide,…
BioNTech & InstaDeep Announce Strategic Collaboration & Form AI Innovation Lab to Develop Novel Immunotherapies
BioNTech SE and InstaDeep Ltd recently announced a multi-year strategic collaboration aimed at applying the latest advances in artificial intelligence (AI) and machine learning (ML) technology to develop….
Foster Corporation Enters Marketing Partnership With Aran Biomedical
Foster Corporation recently announce a new business relationship with Aran Biomedical, a global leader in biomaterial product solutions for implantable medical devices…..
Recipharm Announces Signature of Letter of Intent for Aseptic Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Recipharm, a leading contract development and manufacturing organization (CDMO), recently announced that it has signed a letter of intent with Moderna, a US-based biotech company, to formulate, fill, and….
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
Aravive, Inc. recently announced the company has received guidance from the US FDA on a Phase 3 trial design for AVB-500 in platinum-resistant ovarian cancer…
uniQure Announces Positive Top-Line Data From the HOPE-B Pivotal Trial of Gene Therapy
uniQure N.V. recently announced positive top-line data from its pivotal, Phase 3 HOPE-B gene therapy trial of etranacogene dezaparvovec, an investigational adeno-associated virus five (AAV5)-based…
PMV Pharma Doses First Patient in Phase 1/2 Study of First-in-Class Precision Oncology Therapy
PMV Pharmaceuticals, Inc. recently announced dosing of the first patient in its Phase 1/2 clinical trial evaluating PC14586, the company’s investigational lead compound that targets…
Ocuphire Pharma Announces First Patient Enrolled in Phase 3 Clinical Trial
Ocuphire Pharma, Inc. recently announced the enrollment of the first patient in its MIRA-2 (NCT04620213) Phase 3 registration clinical trial evaluating the safety and efficacy…
Catalent Signs Commercial Supply Agreement With Blueprint Medicines
Catalent recently announced it has entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO (pralsetinib). Developed by Blueprint Medicines, GAVRETO…
AB201 Development as a Potential Treatment for COVID-19 Receives US FDA Fast-Track Designation
ARCA biopharma, Inc. recently announced the US FDA has designated as a Fast-Track development program the investigation of AB201 as a potential treatment for COVID-19.…
